Loading...
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly e...
Na minha lista:
| Udgivet i: | Psoriasis (Auckl) |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6202001/ https://ncbi.nlm.nih.gov/pubmed/30425963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146004 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|